Showing 1 - 6 results of 6 for search 'Andrew F. Shorr', query time: 0.01s Refine Results
  1. 1
    <i>Acinetobacter baumannii</i> Complex Infections: New Treatment Options in the Antibiotic Pipeline

    <i>Acinetobacter baumannii</i> Complex Infections: New Treatment Options in the Antibiotic Pipeline by Noayna Arshad, Wael Azzam, Marya D. Zilberberg, Andrew F. Shorr

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    The Burden of Hospitalization and Rehospitalization Among Patients Hospitalized with Severe Community-Acquired Bacterial Pneumonia in the United States, 2018–2022

    The Burden of Hospitalization and Rehospitalization Among Patients Hospitalized with Severe Community-Acquired Bacterial Pneumonia in the United States, 2018–2022 by Marya D. Zilberberg, Mike Greenberg, Valentin Curt, Andrew F. Shorr

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Descriptive epidemiology and outcomes of emergency department visits with complicated urinary tract infections in the United States, 2016–2018

    Descriptive epidemiology and outcomes of emergency department visits with complicated urinary tract infections in the United States, 2016–2018 by Marya D. Zilberberg, Brian H. Nathanson, Kate Sulham, Andrew F. Shorr

    Published 2022-04-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Unfavorable Outcomes and Their Risk Factors in Hospitalized Patients with <i>Staphylococcus aureus</i> Bacteremia in the US: A Multicenter Retrospective Cohort Study, 2020–2022

    Unfavorable Outcomes and Their Risk Factors in Hospitalized Patients with <i>Staphylococcus aureus</i> Bacteremia in the US: A Multicenter Retrospective Cohort Study, 2020–2022 by Marya D. Zilberberg, Brian H. Nathanson, Rolf Wagenaar, Jan Posthumus, Andrew F. Shorr

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance

    Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance by Andrew F. Shorr, Mark E. Jones, Silke Friedmann, Daniel Ionescu, Mikael Saulay, Jennifer I. Smart, Marc Engelhardt

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance.

    Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance. by Andrew F Shorr, Mark E Jones, Silke Friedmann, Daniel Ionescu, Mikael Saulay, Jennifer I Smart, Marc Engelhardt

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: